FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Pharmaceutically Acceptable Salt topics
Pharmaceutically Acceptable Salt
Pharmaceutically Acceptable Salts
Dimethyl Fumarate
Amelioration
Benzimidazole
Antiviral Agents
Hepatitis C Virus
Antiviral Agent
Antivirals
Hepatitis C
Diabetic Complications
Complication
Kidney Disease
Pyridoxamine
Neurodegenerative Disease

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Pharmaceutically Acceptable Salt patents



      
           
This page is updated frequently with new Pharmaceutically Acceptable Salt-related patents. Subscribe to the Pharmaceutically Acceptable Salt RSS feed to automatically get the update: related Pharmaceutically RSS feeds.

Subscribe to updates on this page: Pharmaceutically Acceptable Salt RSS RSS

Date/App# patent app List of recent Pharmaceutically Acceptable Salt-related patents
04/10/14
20140100537
 Transdermal pharmaceutical preparation and administration of tirofiban patent thumbnailTransdermal pharmaceutical preparation and administration of tirofiban
The present invention provides a titratable transdermal drug delivery system comprising an effective dose of an antithrombotic agent, such as tirofiban, or a pharmaceutically acceptable salt thereof. The dosage of the drug delivered is proportional to the size of the patch applied and achieves 60-85% platelet inhibition.
04/10/14
20140100369
 Pyrrolopyridines as kinase inhibitors patent thumbnailPyrrolopyridines as kinase inhibitors
Compounds of formula i are useful for inhibition of chk1 and/or chk2. Methods of using compounds of formula i and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed..
04/10/14
20140100366
 Process for making thienopyrimidine compounds patent thumbnailProcess for making thienopyrimidine compounds
And stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof.. .
04/10/14
20140100246
 Aclidinium for use in improving the quality of sleep in respiratory patents patent thumbnailAclidinium for use in improving the quality of sleep in respiratory patents
The present invention provides aclidinium or any of its steroisomers or mixture of stereoisomers, or a pharmaceutically acceptable salt or solvate thereof, for improving the quality of sleep in respiratory patients.. .
04/10/14
20140100232
 Combination treatment for rosacea patent thumbnailCombination treatment for rosacea
The invention relates to a method of treating erythema and/or telangiectasia associated with rosacea in a patient in need thereof by topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof to the site of erythema and/or telangiectasia on the skin of the patient. The invention further relates to topical compositions including the combination of compounds and a pharmaceutically acceptable carrier..
04/10/14
20140100231
 Non-nucleoside reverse transcriptase inhibitors patent thumbnailNon-nucleoside reverse transcriptase inhibitors
Are hiv reverse transcriptase inhibitors, wherein r1, r2, re, l, m and z are defined herein. The compounds of formula i and their pharmaceutically acceptable salts are useful in the inhibition of hiv reverse transcriptase, the prophylaxis and treatment of infection by hiv and in the prophylaxis, delay in the onset or progression, and treatment of aids.
04/10/14
20140100223
 Compounds and methods for the treatment of isocitrate dehydrogenase related diseases patent thumbnailCompounds and methods for the treatment of isocitrate dehydrogenase related diseases
The invention relates to compounds of formula i or a pharmaceutically acceptable salt, ester or prodrug thereof:. .
04/10/14
20140100218
 Treatment of mild and moderate alzheimer's disease patent thumbnailTreatment of mild and moderate alzheimer's disease
The present invention relates to methods of treatment using [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl amine (“compound i”) or a pharmaceutically acceptable salt thereof. In various embodiments, the methods of treatment include treatment of mild-to-moderate dementia of alzheimer's type, diabetes, insomnia, and other indications.
04/10/14
20140100179
 Novel urea compounds patent thumbnailNovel urea compounds
Or a pharmaceutically acceptable salt thereof.. .
04/10/14
20140099283
 2'-chloro nucleoside analogs for hcv infection patent thumbnail2'-chloro nucleoside analogs for hcv infection
Or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein b, z and pd are as described herein.. .
04/03/14
20140094522
Compound formulations of 2-amino-1, 3-propanediol compounds
Pharmaceutical concentrate formulations comprising 2-amino-1,3-propanediol compounds, analogs thereof and salts thereof, particularly 2-amino-2-[2-(4-octylphenyl)ethyl]-propane-1,3-diol or a pharmaceutically acceptable salt thereof in an organic solvent or semi-aqueous solvent and methods for administration of the undiluted and diluted concentrate are provided.. .
04/03/14
20140094498
Methods and compositions for treating post-operative pain comprising clonidine
The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a therapeutically effective amount of clonidine or pharmaceutically acceptable salt thereof and a polymer; wherein the depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the depot is capable of releasing (i) about 5% to about 45% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a first period of up to 48 hours and (ii) about 55% to about 95% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a subsequent period of at least 3 days.. .
04/03/14
20140094491
Dimethyl-benzoic acid compounds
Or a pharmaceutically acceptable salt thereof.. .
04/03/14
20140094489
Heterocyclic carboxylic acid ester derivative
Or a pharmaceutically acceptable salt thereof.. .
04/03/14
20140094482
Benzazocine-ring compound inhibition of tau hyperphosphorylation
A method of inhibiting hyperphosphorylation of the tau protein and/or a tlr4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system a flna-binding effective amount of a flna-binding benzazocine-ring compound or a pharmaceutically acceptable salt thereof such as a) an opioid receptor antagonist compound or b) a mixed opioid receptor agonist and antagonist (agonist/antagonist) compound, c) an opioid receptor agonist compound or d) an enantiomer of an opioid receptor interacting compound, that binds to a pentapeptide of filamin a (flna) of seq id no: 1.
04/03/14
20140094474
Androgen receptor modulating carboxamides
Wherein rx, rz, r9, r10, r14, r14′, r15, r15′, a and b are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds possess utility as tissue-selective androgen receptor modulators (sarm) and are useful as medicaments in the treatment of prostate cancer and other ar dependent conditions and diseases where ar antagonism is desired..
04/03/14
20140094473
Inhibitors of influenza viruses replication
Or a pharmaceutically acceptable salt thereof, wherein the values of structural formula (i) are as described herein. A compound is represented by structural formula (i) or a pharmaceutically acceptable salt thereof, wherein the values of structural formula (i) are as described herein.
04/03/14
20140094470
Combination treatment for dermatological conditions
The invention relates to a method of treating dermatological conditions or symptoms associated therewith in a patient in need thereof by topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof to the affected area of skin on the patient. The invention further relates to topical compositions including the combination of compounds and a pharmaceutically acceptable carrier..
04/03/14
20140094459
Tyrosine kinase inhibitors
The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular blk, bmx, egfr, her2, her4, itk, tec, btk, and txk and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof..
04/03/14
20140094454
Tetrahydropyrrolothiazine compounds
Or a pharmaceutically acceptable salt thereof.. .
04/03/14
20140094449
Treatment of bipolar disorder
The invention relates to sulphur- and/or selenium-containing compounds that can inhibit the enzyme inositol mono-phosphatase (impase), and which can be used in treating conditions that are treatable through inhibition of this enzyme, such as bi-polar disorder, the compounds having a structure of formula (i), or is a pharmaceutically acceptable salt thereof; formula (i); in which: e is s or se and each of phenyl rings a and b is optionally substituted with one or more substituents, in which each substituent is selected independently from: (1) a halogen, which is preferably selected from f, cl and br; (2) c1-c4 alkyl, such as c1-c2 alkyl or c1 alkyl, optionally substituted with one or more halogen atoms, each of which is preferably selected from f, cl and br; and (3) c1-c4 alkoxy, such as c1-c2 alkoxy or c1 alkoxy; optionally substituted with one or more halogen atoms, each of which is preferably selected from f, cl and br.. .
04/03/14
20140094447
Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
Pharmaceutical compositions and methods for treating or preventing bacterial infections are disclosed. The pharmaceutical compositions typically comprise pharmaceutically effective amount of: (a) sulbactam or a pharmaceutically acceptable salt thereof, and (b) at least one beta-lactamase inhibitor or a pharmaceutically acceptable salt thereof, with the provision that the beta-lactamase inhibitor is not sulbactam..
04/03/14
20140094446
Cyclic amino acids for the treatment of pain
Compositions comprising cyclic amino acids or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier. Said compositions are for use in the treatment of pain.
04/03/14
20140094443
Tgr5 modulators and methods of use thereof
Or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. The compounds of formula a are tgr5 modulators useful for the treatment of various diseases, including obesity, insulin sensitivity, inflammation, cholestasis, and bile desaturation..
04/03/14
20140094435
Use of dextran sulfate
A method of inhibiting instant blood-mediated inflammatory reaction (ibmir) in a patient, comprises administering a therapeutically effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof. A method of inhibiting morphological disruption of a transplanted cell transplant in a patient comprises administering a therapeutically effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof, to a patient.
04/03/14
20140094405
Cholesterol derivatives of inhibitors of viral fusion
The present invention relates to compounds comprising at least ten contiguous amino acids of the hr2 domain of a type 1 viral fusogenic protein of an enveloped virus, or a derivative thereof, attached at the c-terminal to cholesterol or a derivative thereof; or a pharmaceutically acceptable salt thereof which inhibit viral fusion. Thus compounds of the invention are useful to prevent or treat diseases caused by an enveloped virus..
04/03/14
20140094403
Enopeptins, uses thereof, and methods of synthesis thereto
Provided herein are inventive enopeptin compounds of formula (i): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Further provided are methods of preparation, use, and treatment..
04/03/14
20140094402
Lantibiotic nai-802, pharmaceutically acceptable salts, compositions and uses thereof
The present invention concerns novel lantibiotic compounds, processes for the isolation and preparation thereof, pharmaceutical compositions containing the same, pharmaceutical acceptable salts thereof, and methods of use of the lantibiotics as antibacterial agents.. .
04/03/14
20140093570
Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein
The present disclosure relates to crystalline form of (s)—n—((s)-1-cyclohexyl-2-{(s)-2-[4-(4-fluorobenzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide, salts and hydrates thereof. This disclosure also relates to solid oral formulation of (s)—n—((s)-1-cyclohexyl-2-{(s)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide, pharmaceutically acceptable salts, solvates (including hydrates) thereof, as well as methods of treatment using the same..
04/03/14
20140093566
Pharmaceutical formulations of a substituted diaminopurine
Provided herein are pharmaceutical formulations, comprising 4-((9-((3s)-tetrahydro-3-furanyl)-8-((2,4,6-trifluorophenyl)amino)-9h-purin-2-yl)amino)-trans-cyclohexanol, including pharmaceutically acceptable salts, solvates, isomers, isotopologues, tautomers and racemic mixtures thereof, and a pharmaceutically acceptable excipient; and their use for treating or preventing disease.. .
04/03/14
20140093565
A pharmaceutical composition comprising a hdac inhibitor and a steroid and the use thereof
The invention relates to a pharmaceutical composition comprising a hdac inhibitor, a pharmaceutically acceptable acid or a salt thereof or a mixture thereof and a steroid or a pharmaceutically acceptable salt thereof as well use of said pharmaceutical composition for the treatment of cancer as a pretreatment prior to other treatments. Said hdac inhibitor or steroid may alternatively be administrated separately prior to additional treatments..
04/03/14
20140093564
Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with simvastatin
The present invention is directed to novel pharmaceutical compositions comprising fixed dose combinations of a dipeptidyl peptidase-4 inhibitor (dpp-4 inhibitor), or a pharmaceutically acceptable salt thereof, and simvastatin, or pharmaceutically acceptable salt thereof, methods of preparing such pharmaceutical compositions, and methods of treating type 2 diabetes and hypercholesterolemia with such pharmaceutical compositions. In particular, the invention is directed to pharmaceutical compositions comprising fixed-dose combinations of sitagliptin phosphate and simvastatin..
04/03/14
20140093505
Pyridonaphthyridine pi3k/mtor dual inhibitors and preparation and use thereof
The present invention relates to a pyridonaphthyridine compound as represented by general formula (i), which has a dual pi3k and mtor inhibition effect, and its pharmaceutically acceptable salt, stereoisomer and deuteride thereof, wherein r1, r2, r3, r4, r5, r6, r7 and x are as defined in the specification; the present invention also relates to a method for preparing said compound, a pharmaceutical composition and a pharmaceutical formulation containing said compound, and uses of said compound in treating and/or preventing a proliferative disease and in the manufacture of a medicament for treating and/or preventing a proliferative disease.. .
04/03/14
20140093502
Immunosuppressive combination and its use in the treatment or prophylaxis of insulin-producing cell graft rejection
A pharmaceutical combination comprising an accelerated lymphocyte homing agent in free form or in pharmaceutically acceptable salt form, and one or more compounds selected from the group consisting of an antibody to the il-2 receptor, an immunosuppressive macrocyclic lactone and a soluble human complement inhibitor is used to treat or prevent insulin-producing cell graft rejection.. .
04/03/14
20140093484
Use of dextran sulfate
A graft composition intended for transplantation into a patient comprises an injection solution comprising an isolated cell transplant and dextran sulfate, or a pharmaceutically acceptable salt thereof.. .
03/27/14
20140088302
Novel cephem compound having catechol or pseudo-catechol structure
Wherein each symbol is as defined in the specification, or an amino-protected compound when the amino group is present on the ring in the 7-side chain, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.. .
03/27/14
20140088184
Use of epigallocatechin gallate as an antiviral agent against infections by the hepatitis c virus
The present invention relates to a flavonoid compound having the formula i, where r3, r5 and/or r7 is a group having the formula ii, or r1 and r2 are both oh groups, or to one of the pharmaceutically acceptable salts or esters thereof, for use as an antiviral agent in the treatment and/or prevention of a hepatitis c virus (hcv) infection. The invention also relates to an ex vivo method for reducing the infectivity of hcv or for inactivating hcv, including a step of contacting said hepatitis c virus with a compound having the formula (i)..
03/27/14
20140088178
Combination of anti-clusterin oligonucleotide with androgen receptor antagonist for the treatment of prostate cancer
Or a pharmaceutically acceptable salt thereof, each in an amount that when in combination with the other is effective to treat the mammalian subject.. .
03/27/14
20140088166
Process of making and using pharmaceutical formulations of antineoplastic agents
In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, l-histidine, l-threonine, l-asparagine, l-serine, l-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.. .
03/27/14
20140088165
Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors
Or a pharmaceutically acceptable salt thereof, wherein r1, r2, r3, r4, r6, a1, a2, x1, s and m are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses.
03/27/14
20140088155
D-methadone for the treatment of psychiatric symptoms
The present invention relates to a method of treating psychiatric symptoms in a subject having a nmda receptor and a ne receptor which includes administering d-methadone, d-methadol, d-alpha-acetylmethadol, l-alpha-acetylmethadol, d-alpha-normethadol, l-alpha-normethadol, pharmaceutically acceptable salts thereof, or mixtures thereof, to the subject under conditions effective for the substance to bind to the nmda receptor and ne receptor of the subject.. .
03/27/14
20140088152
Composition for preventing and treating cardiovascular diseases, containing pyrazole derivative
The present invention provides a composition comprising a pyrazole derivative compound and a pharmaceutically acceptable salt thereof. The composition is remarkably effective for preventing and treating cardiovascular diseases..
03/27/14
20140088147
Method of inhibiting mutant c-kit
Or pharmaceutically acceptable salt thereof.. .
03/27/14
20140088144
Inhibiting microbial infections
A method of inhibiting a microbial infection can include: providing a compound of the invention or prodrugs or pharmaceutically acceptable salts thereof; and administering the compound to a subject in a therapeutically effective amount to inhibit the microbial infection. The therapeutically effective amount can be sufficient to inhibit a biological activity of a transcriptional activator of the microbe.
03/27/14
20140088143
Method of inhibiting constitutively active phosphorylated flt3 kinase
Or pharmaceutically acceptable salt thereof.. .
03/27/14
20140088142
Modulators of cystic fibrosis transmembrane conductance regulator
Or a pharmaceutically acceptable salt thereof, wherein r is cooh or ch2oh.. .
03/27/14
20140088130
Hexahydrodibenzo[a,g]quinolizine compound, preparation method thereof, pharmaceutical composition and use thereof
The present invention relates to a novel hexahydrodibenzo[a,g]quinoline compound represented by general formula (i) and its derivatives, enantiomer, diastereoisomer, raceme and mixtures thereof, as well as pharmaceutically acceptable salts thereof. The present invention further relates to a method for preparing the compound, and the compound has good prevention and treatment effect on neurological diseases, especially diseases associated with dopamine receptor and 5-hydroxytryptamine receptor.
03/27/14
20140088126
Rosuvastatin enantiomer compounds
The invention discloses a method for the treatment of diseases, particularly those diseases characterized by diminished or aberrant cellular function, including aids, cancer, and alzheimer's disease. The method comprises administering a therapeutically effective amount of rosuvastatin enantiomer compounds in their (3r, 5r), (3s, 5r), or (3s, 5s) configurations, or pharmaceutically acceptable salts thereof.
03/27/14
20140088123
Treatment of lung cancer
Disclosed are methods of treating lung cancer by administering to a human in need thereof effective amounts of fts, or various analogs thereof, or a pharmaceutically acceptable salt thereof, optionally, in combination with a chemotherapeutic agent. Chemotherapeutic agents, and combinations thereof, for use with fts, its analogs, or its salts are also disclosed..
03/27/14
20140088121
Hsp90 inhibitors
And pharmaceutically acceptable salts thereof wherein z1, z2, z3, xa, xb, xc, xd, y, x2, and x4 are as defined herein, compositions comprising an effective amount of a compound of formula (ia) and/or (ib), and methods to treat or prevent a condition, such cancer which overexpresses her-kinases, comprising administering to an patient in need thereof a therapeutically effective amount of a compound of formula (ia) or (ib). The disclosure further relates to compounds of formulae (ia) and ib) in which x2 is a leaving for introducing a radiolabeled atom, such as 124i or 131i and to methods of using such compounds in the preparation of radiolabeled compounds, particularly for use in imaging..
03/27/14
20140088119
Muscarinic agonists as enhancers of working memory and cognitive flexibility
Methods and compositions for treating a mental condition in a subject in need thereof, includes administering to a subject in need thereof an effective amount of a cdd-102a compound [5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine], or a pharmaceutically acceptable salt or hydrate thereof pharmaceutically acceptable salt or hydrate thereof.. .
03/27/14
20140088117
Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of formula i, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein r2 is a cyclic ether and x is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting pim kinase, and for treating disorders such as cancer mediated by pim kinase. Methods of using compounds of formula i for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed..
03/27/14
20140088114
Fused bicyclic kinase inhibitors
Compounds of formula (i), pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of met, ron, alk, ir, or igf-1r. This abstract is not limiting of the invention..
03/27/14
20140088109
N-((1r,2s,5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
Or a pharmaceutically acceptable salt, solvate or prodrug, thereof, having unexpected dual ccr-2 and ccr-5 receptor activity. Crystalline forms, metabolites, pharmaceutical compositions containing the same and methods of using the same as agents for the treatment of inflammatory diseases, allergic, autoimmune, metabolic, cancer and/or cardiovascular diseases are also disclosed.
03/27/14
20140088104
Novel small-molecules as therapeutics
The present invention provides compounds of formula (i), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful in treating central nervous system disorders, such as anxiety disorders or depression..
03/27/14
20140088097
Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
And the tautomers and the salts thereof, particularly the pharmaceutically acceptable salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on epithelial sodium channels, the use thereof for the treatment of diseases, particularly diseases of the lungs and airways.. .
03/27/14
20140088082
Inhibitors of the plasmodial surface anion channel as antimalarials
Or a pharmaceutically acceptable salt thereof, wherein r1 to r7 are as described herein.. .
03/27/14
20140088081
Amino-heterocyclic compounds
And pharmaceutically acceptable salts thereof, wherein r1, r2, r3, a, and n are as defined herein. Pharmaceutical compositions containing the compounds of formula i, and uses thereof in treating neurodegenerative and cognitive disorders, such as alzheimer's disease and schizophrenia, are also provided..
03/27/14
20140088063
Agents for treating neurodegenerative disorders
Wherein r, x and n are as defined in specification or pharmaceutically acceptable salts thereof, solvates thereof such as hydrates, and pharmaceutical compositions containing such compounds, with the proviso that the compound of formula (i) is not meso-1s,2s,1′r,2′r-1-[2-(3,3-dimethyldiaziridin-1-yl)ethyl]-3,3-dimethyldiaziridine (r═me, x═ch2, n=2) (formula i′).. .
03/27/14
20140088062
Compositions comprising fusidic acid and packages therefor
Described are solid pharmaceutical compositions of fusidic acid, and pharmaceutically acceptable salts thereof, dosage units of the pharmaceutical compositions, and packages for pharmaceutical compositions of fusidic acid, and pharmaceutically acceptable salts thereof, which increase stability against the degradation of the fusidic acid, and pharmaceutically acceptable salts thereof. Also described are uses of the pharmaceutical compositions and dosage units in treating diseases..
03/27/14
20140088005
Double-acylated glp-1 derivatives
The invention relates to a derivative of a glp-1 analogue, which analogue comprises a first k residue at a position corresponding to position 27 of glp-1(7-37) (seq id no: 1); a second k residue at a position corresponding to position t of glp-1(7-37), where t is an integer in the range of 7-37 except 18 and 27; and a maximum of ten amino acid changes as compared to glp-1(7-37); wherein the first k residue is designated k27, and the second k residue is designated kt; which derivative comprises two albumin binding moieties attached to k27 and kt, respectively, via a linker, wherein the albumin binding moiety comprises a protracting moiety selected from hooc—(ch2)x—co— and hooc—c6h4-0-(ch2)y—co—; in which x is an integer in the range of 6-16, and y is an integer in the range of 3-17; wherein the linker comprises an element of the formula —nh—(ch2)2—(o—(ch2)2)k—o—(ch2)n—co—, wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel glp-1 analogues.


Popular terms: [SEARCH]

Pharmaceutically Acceptable Salt topics: Pharmaceutically Acceptable Salt, Pharmaceutically Acceptable Salts, Dimethyl Fumarate, Amelioration, Benzimidazole, Antiviral Agents, Hepatitis C Virus, Antiviral Agent, Antivirals, Hepatitis C, Diabetic Complications, Complication, Kidney Disease, Pyridoxamine, Neurodegenerative Disease

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patents related to Pharmaceutically Acceptable Salt for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Pharmaceutically Acceptable Salt with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.4213

5732

2 - 1 - 84